Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[G-CSF in radiochemotherapy]

M Riepl1, R Fietkau, R Sauer

  • 1Strahlentherapeutische Klinik und Poliklinik, Universität Erlangen-Nürnberg.

Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial.

ESMO open·2026
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same author

DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Is less more? Revisiting elective nodal irradiation in head and neck cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Postoperative brachytherapy alone for 217 patients with early-stage oral cavity squamous cell carcinoma.

Clinical and translational radiation oncology·2025
Same author

Implant-based reconstruction and adjuvant radiotherapy in breast cancer patients-current status and DEGRO recommendations.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same journal

Effects of intrafractional motion on targeting accuracy in frameless single-isocenter multi-target stereotactic radiosurgery.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

[Evolution of metastases in non-small-cell lung cancer: preliminary results from the TRACERx-PEACE study].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

[SAKK 09/10: dose-intensified salvage radiotherapy for biochemical recurrence after prostatectomy-no benefit, but additional toxicity?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Helical intensity-modulated radiation therapy vs. C-arm-based volumetric modulated arc therapy for sinonasal tumours: organ at risk sparing and treatment efficiency.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Delta radiomics for predicting early radiation-induced lung injury after thoracic radiotherapy: a retrospective paired-CT study.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
See all related articles

Granulocyte-colony stimulating factor (G-CSF) effectively treats severe leukopenia during radio(chemo)therapy. Early intervention with G-CSF prevents therapy interruptions and avoids critical low white blood cell counts.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Context:

  • Granulocyte-colony stimulating factor (G-CSF) is known to shorten chemotherapy-induced leukopenia and increase granulocyte levels during radiotherapy.
  • Limited data exists on the combined use of G-CSF with simultaneous radiochemotherapy.

Purpose:

  • To evaluate the efficacy and safety of G-CSF in patients undergoing radiotherapy or combined radiochemotherapy.
  • To determine optimal G-CSF application criteria for managing severe or rapidly decreasing leukopenia.

Summary:

  • G-CSF was administered to 28 patients (16 with severe leukopenia, 11 with moderate leukopenia) undergoing radiotherapy or radiochemotherapy.
  • In severe leukopenia cases, leukocytes increased within 3 days, with minimal radiotherapy interruptions. In moderate leukopenia, leukocytes increased rapidly, avoiding interruptions.

Related Experiment Videos

  • No significant side effects of G-CSF were observed.

    • Impact:

    • G-CSF is a valuable intervention for managing leukopenia during radio(chemo)therapy, enabling treatment continuation.
    • Establishing clear G-CSF application thresholds can prevent unavoidable therapy delays or severe leukopenia.
    • This study supports the use of G-CSF to maintain treatment integrity in oncology patients.